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http://dx.doi.org/10.1016/j.ccr.2013.05.007SUMMARYMost deaths from breast cancer result from tumor recurrence, but mechanisms underlying tumor relapse are
largely unknown. We now report that Par-4 is downregulated during tumor recurrence and that Par-4 downre-
gulation is necessary and sufficient to promote recurrence. Tumor cells with low Par-4 expression survive ther-
apy by evading a program of Par-4-dependent multinucleation and apoptosis that is otherwise engaged
following treatment. Low Par-4 expression is associated with poor response to neoadjuvant chemotherapy
andan increased riskof relapse inpatientswithbreastcancer,andPar-4 isdownregulated in residual tumorcells
that survive neoadjuvant chemotherapy.Our findings identify Par-4-inducedmultinucleation as amechanismof
cell death in oncogene-addicted cells and establish Par-4 as a negative regulator of breast cancer recurrence.INTRODUCTION
Most deaths from breast cancer result from disease relapse
following treatment of the primary tumor. Although 5-year sur-
vival rates for patients with breast cancer are relatively high
compared to other cancers, tumors can recur up to 20 years after
diagnosis (Saphner et al., 1996). This reflects the fact that resid-
ual cancer cells, termed minimal residual disease, often survive
surgery, radiation, and adjuvant therapy and serve as a reservoir
for breast cancer recurrence. Consistent with this, disseminated
tumor cells (DTCs) are present in the bone marrow of up to 40%
of patients with breast cancer at diagnosis, and their presence
and number following adjuvant therapy are strong independent
predictors of recurrence risk (reviewed in Bednarz-Knoll et al.,
2011). These observations suggest that the ability of residual
cancer cells to survive treatment and persist in a clinically unde-Significance
Recurrent breast cancer is typically an incurable disease. Cons
surgery, radiation, and adjuvant therapy is the most importan
that persist following treatment constitute the reservoir from
the successful treatment of human cancers. Accordingly, unde
vive treatment is a critical research priority. Our findings establi
in women as a mechanism of tumor cell survival and recurren
therapies that target pathways repressed by Par-4—or that res
30 Cancer Cell 24, 30–44, July 8, 2013 ª2013 Elsevier Inc.tectable state is a common precursor to the development of
recurrent disease.
Although the molecular and cellular events that contribute to
primary tumorigenesis in the breast have been intensively stud-
ied, much less is known about pathways that contribute to the
survival and recurrence of residual breast cancer cells. This is
due, in part, to the difficulty in isolating and analyzing residual tu-
mor cells in humans, the paucity of clinical samples from patients
with recurrent disease, and the need for animal models that faith-
fully recapitulate essential aspects of minimal residual disease
and recurrence.
To address this critical gap, our laboratory has developed con-
ditional transgenic mouse models for HER2/neu (MMTV-rtTA;
TetO-HER2/neu), MYC (MMTV-rtTA;TetO-MYC), and Wnt1/p53
(MMTV-rtTA;TetO-Wnt1;p53/+)-induced mammary tumorigen-
esis (D’Cruz et al., 2001; Gunther et al., 2003; Moody et al.,equently, the propensity of breast cancers to recur following
t determinant of clinical outcome. Residual neoplastic cells
which recurrent tumors arise and are a major obstacle to
rstanding themechanisms by which residual tumor cells sur-
sh downregulation of the tumor suppressor Par-4 inmice and
ce following targeted therapy and chemotherapy. As such,
tore Par-4 expression—may hold significant clinical promise.
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Par-4 Inhibits Breast Cancer Recurrence2002, 2005; Boxer et al., 2004) that permit analysis of the prop-
erties of minimal residual disease and the mechanisms of tumor
recurrence. These models exhibit key features of breast cancer
progression as it occurs in women, including the survival of re-
sidual cancer cells following therapy and their eventual sponta-
neous recurrence.
In each of thesemodels, administration of doxycycline (dox) in-
duces oncogene expression in the mammary epithelium, which
in turn results in the formation of invasive primary mammary ad-
enocarcinomas.Moreover, akin to the responses of some human
cancers to targeted therapies, themajority of oncogene-induced
mammary tumors in mice regress to a nonpalpable state
following oncogene downregulation, illustrating the phenome-
non of oncogene addiction. However, as is frequently observed
in patients with breast cancer, mice in which primary tumors
have regressed spontaneously develop recurrent cancers
following a variable latency period. Because recurrent tumors
in these models occur in the absence of expression of the initi-
ating oncogene, this suggests that mammary tumors escape
and recur by activating alternate growth and survival pathways.
Based on these observations, we reasoned that the specific
mechanisms by which tumor cells survive oncogene downregu-
lation and recur in mice could provide clues to pathways that
contribute to breast cancer relapse in patients. In this regard,
we considered the tumor suppressor, prostate apoptosis
response 4 (Par-4), to be an attractive candidate. Par-4, encoded
by the Pawr gene, is a proapoptotic protein that is upregulated in
response to apoptotic stimuli and required for cell death in mul-
tiple contexts (Sells et al., 1994, 1997; Dı´az-Meco et al., 1996).
Par-4 is silenced in a variety of human cancers, and its re-expres-
sion induces cell death in some cancer cell lines (reviewed in
Ranganathan and Rangnekar, 2005). Consistent with its proapo-
ptotic effects, mice lacking Par-4 are tumor prone and exhibit an
increase in spontaneous tumorigenesis as well as increased sus-
ceptibility to chemical and hormone-induced cancers (reviewed
in Diaz-Meco and Abu-Baker, 2009). Thus, Par-4 is a bona fide
tumor suppressor and a critical regulator of tumor cell survival.
Emerging data have implicated Par-4 downregulation as a
prognostic factor in breast cancer. Low Par-4 expression has
recently been shown to be associated with reduced overall sur-
vival in two patient cohorts, raising the possibility that Par-4
downregulation may be associated with an increased risk of
recurrence (Me´ndez-Lo´pez et al., 2010; Nagai et al., 2010). How-
ever, one of these studies examined only a small patient cohort
(Me´ndez-Lo´pez et al., 2010), and the other found an association
between Par-4 and overall survival, but not disease-free survival
(Nagai et al., 2010). As such, the relationship between Par-4
downregulation and breast cancer recurrence remains unclear.
Moreover, the mechanisms underlying the apparent association
between low Par-4 expression and tumor recurrence, as well as
whether Par-4 downregulation functionally contributes to breast
cancer recurrence, have not been addressed.
RESULTS
Par-4 Is Downregulated during Tumor Recurrence in
Mice
We reasoned that genetically engineered mouse models for tu-
mor recurrence could provide insight into the functional effectsof Par-4 downregulation on breast cancer relapse.We first asked
whether Par-4 expression is altered during the recurrence of pri-
mary mammary tumors induced by the HER2/neu, MYC, or
Wnt1;p53+/ oncogenic pathways. Quantitative reverse-tran-
scription PCR and immunoblotting performed on primary and
spontaneous recurrent tumors arising in MTB/TAN, MTB/TOM,
and MTB/TWnt1 transgenic mice revealed that Par-4 mRNA
and protein were downregulated in recurrent tumors in all three
models (Figures 1A–1E). Immunofluorescence staining for Par-
4 in HER2/neu-induced tumors confirmed that whereas Par-4
was readily detectable in primary tumors, its expression was
markedly downregulated in recurrent tumors (Figure 1F). These
results demonstrate that Par-4 is frequently—and spontane-
ously—downregulated during the process of recurrence inmam-
mary tumors induced by three different oncogenic pathways
relevant to human cancer.
Par-4 Is Downregulated in Tumors that Recur following
Chemotherapy
The aforementioned results indicated that Par-4 is downregu-
lated in recurrent tumors that arise spontaneously in MTB/TAN
mice following primary tumor regression induced by HER2/neu
downregulation, which is a surrogate for targeted therapy. How-
ever, whereas women with HER2/neu-amplified tumors are typi-
cally treated with targeted therapies, such as trastuzumab or
lapatinib, most patients with breast cancer receive adjuvant
chemotherapy. As such, the majority of tumor recurrences in
women arise in the context of prior treatment with cytotoxic
chemotherapeutic agents. Therefore, we asked whether Par-4
is downregulated in recurrent tumors that arise following
chemotherapy.
Mice bearing orthotopic mammary tumors generated by injec-
tion of tumor cells from HER2/neu-induced primary tumors
arising in MTB/TAN mice were treated with Adriamycin and
cyclophosphamide (AC) for 2 weeks, followed by paclitaxel (T)
for 2 weeks. AC plus T led to marked regression of all tumors,
whereas untreated control tumors continued to grow (Figures
S1A and S1B available online). Following tumor regression,
treatment was stopped, and mice were monitored for relapse.
All tumors relapsed within 3 weeks of treatment cessation (Fig-
ure S1B), and tumors that relapsed following chemotherapy ex-
hibited a marked reduction in Par-4 expression (Figure S1C).
This suggests that Par-4 is downregulated in tumors that relapse
following chemotherapy as well as oncogene downregulation.
Low Par-4 Predicts an Increased Risk of Recurrence in
Women with Breast Cancer
In light of our observation that Par-4 is frequently downregulated
during tumor recurrence in mice, and given the preliminary
finding that low Par-4 expression is associated with poor prog-
nosis in at least some patients with breast cancer (Me´ndez-
Lo´pez et al., 2010; Nagai et al., 2010), we asked whether low
Par-4 expression is associated with an increased risk of recur-
rence in a broader panel of patients with breast cancer. We ob-
tained gene expression data from publicly available human
breast cancer data sets for which clinical outcome was available
(Table S1) and examined the relationship between Par-4 expres-
sion and recurrence-free survival (RFS). Using both the Cox pro-
portional hazards (PH) model, which treats Par-4 expression as aCancer Cell 24, 30–44, July 8, 2013 ª2013 Elsevier Inc. 31
Figure 1. Par-4 Is Downregulated in Recur-
rent Mammary Tumors
(A–D) Quantitative reverse-transcription PCR
analysis (A) and western analysis (B–D) showing
Par-4 expression in primary (Pri) and recurrent
(Rec) HER2/neu, MYC, and Wnt1;p53+/ tumors.
(E) Quantification of Par-4 protein levels, normal-
ized to tubulin.
(F) Immunofluorescence (IF) analysis of Par-4 in
primary and recurrent HER2/neu tumors. Scale
bars, 50 mm.
Error bars denote mean ± SEM. *p < 0.05; **p <
0.01; ***p < 0.001.
See also Figure S1.
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divides tumors into two groups based upon Par-4 expression,
we found that women with breast cancers expressing low levels
of Par-4 exhibited a significantly increased risk of recurrence
over a 5-year period compared to women whose breast cancers
expressed higher levels of Par-4 (Figures S2A–S2D; Table S2;
Cox PH model, hazards ratio [HR] range: 0.21–0.62; outcome-
oriented model, HR range: 0.11–0.44).
We next asked whether the association between Par-4 down-
regulation and decreased RFS is independent of other clinico-
pathological variables. We first assessedwhether Par-4 downre-
gulation is associated with aggressive subtypes of human breast
cancer. Indeed, Par-4 expression was lower in estrogen receptor
(ER) compared to ER+ tumors, in basal-like tumors compared
to other molecular subtypes, and in high-grade (grade 3)
compared to lower-grade tumors in three data sets (Table S3).
In contrast, Par-4 expression was similar between HER2+ and
HER2 tumors and between tumors with lymph node metasta-
ses and those without (data not shown).
Because ER, basal-like, and high-grade breast cancers are
each associated with poor clinical outcome, we wished to deter-
mine whether the reduced RFS observed in patients with breast
cancer with lowPar-4 expressionwas an indirect reflection of the
association between reduced Par-4 expression and these clini-
copathological markers or, alternately, whether reduced Par-4
expression might be an independent prognostic factor. After
individually adjusting for ER status, basal-like subtype, and tu-
mor grade, the association between low Par-4 expression and
decreased RFS remained significant in the majority of data32 Cancer Cell 24, 30–44, July 8, 2013 ª2013 Elsevier Inc.sets (Table S4). These findings identify
low Par-4 expression as an independent
predictor of decreased RFS in women
with breast cancer.
We previously demonstrated that Snail
expression promotes mammary tumor
recurrence in mice, induces epithelial-
to-mesenchymal transition (EMT) in
mouse mammary tumor cells, and is
associated with decreased RFS in
women with breast cancer. Therefore,
we assessed the relationship among
Par-4 downregulation, Snail upregula-
tion, EMT, and RFS in the aforementioned
human breast cancer data sets. Par-4and Snail were not significantly correlated in these data sets
(r = 0.02; p = 0.65), and the association between low Par-4
expression and decreased RFS remained after correcting for
Snail expression (Table S5).
Low Par-4 Predicts a Decreased Response to
Chemotherapy in Women with Breast Cancer
Given the proapoptotic function of Par-4, we reasoned that low
Par-4 expression might be associated with an increased ability
of tumor cells to survive chemotherapy and that this might un-
derlie the increased risk of recurrence associated with tumors
expressing low levels of Par-4. To address this question, we
examined Par-4 expression in human breast cancers in women
enrolled in the I-SPY 1 TRIAL treated with neoadjuvant chemo-
therapy (Esserman et al., 2012). In this trial, patients with locally
advanced breast cancer underwent tumor biopsy prior to
receiving neoadjuvant chemotherapy. Following chemotherapy,
residual primary tumors were surgically resected, and gene
expression profiles weremeasured on paired biopsies and resid-
ual tumors.
First, we examined the relationship between RFS and Par-4
expression in primary breast cancers prior to the administration
of chemotherapy. Consistent with our prior findings, patients in
the I-SPY 1 TRIAL whose breast cancers expressed low levels
of Par-4 were more likely to relapse over a 5-year period using
either a Cox PH model (HR = 0.66, 95% confidence interval
[CI] 0.46–0.94; p = 0.02) or an outcome-oriented cut-point
approach (HR = 0.43, 95% CI 0.23–0.8; p = 0.028; Figure 2A;
Table S2).
Figure 2. Decreased Par-4 Expression Pre-
dicts Poor Response to Neoadjuvant
Chemotherapy and Is Selected for following
Treatment
(A) Five-year RFS for patients with breast cancer in
the I-SPY1 neoadjuvant trial with HR, 95% CIs,
and adjusted p value.
(B) Par-4 expression in primary human breast
cancers prior to treatment as a function of RCB
following neoadjuvant therapy.
(C and D) Par-4 expression in matched pretreat-
ment breast cancer biopsies and residual tumor
following neoadjuvant therapy at surgery.
Error bars denote mean ± SEM. *p < 0.05; **p <
0.01.
See also Figure S2 and Tables S1–S5.
Cancer Cell
Par-4 Inhibits Breast Cancer RecurrenceNext, we examined patient responses to neoadjuvant chemo-
therapy as a function of Par-4 expression in their breast cancers
prior to chemotherapy. To quantify tumor response, residual can-
cer burden (RCB) was assessed at the time of surgery, which
takes into account parameters such as residual tumor size, cellu-
larity, and lymph node involvement. We separated tumors into
three groups based upon RCB class. The first group contained
RCB 0 and I tumors, which have the lowest residual cancer
burden. The second group contained RCB II tumors. The third
group contained RCB III tumors, which exhibited minimal
response or progression in the breast and/or lymph nodes at
the time of surgery, and have the highest burden. Because RCB
0 and I tumors are associated with a low risk of recurrence, these
classes were combined for our analysis (Symmans et al., 2007).
Analysis of the correlation between Par-4 expression and RCB
class revealed that tumors with the poorest response to neoad-
juvant chemotherapy (i.e., the greatest amount of residual
disease, RCB class III) exhibited substantially lower Par-4
expression prior to therapy than tumors that exhibited a greater
response to chemotherapy (RCB class 0 plus I and RCB class II;
Figure 2B). This indicates that low Par-4 expression in locally
advanced human breast cancers is associated with poor
response to chemotherapy, suggesting that the observed rela-
tionship between low Par-4 expression and decreased RFS
may reflect, at least in part, a decreased response to therapy
in breast cancers expressing low levels of Par-4.
Par-4 Is Downregulated in Human Breast Cancer Cells
that Survive Chemotherapy
We next hypothesized that cancer cells with low Par-4 expres-
sion might preferentially survive chemotherapy in women with
breast cancer. If this were the case, we reasoned that cells sur-
viving chemotherapy would, on average, exhibit lower Par-4
expression than bulk tumor cells prior to treatment.
To test this hypothesis, we compared Par-4 expression in the
I-SPY 1 TRIAL in matched primary tumor biopsies and residualCancer Cell 24,tumors harvested at surgery following
neoadjuvant chemotherapy. We found
that Par-4 expression decreased
following treatment in 13 of the 21 pa-
tients for whom expression data were
available at both pre- and posttreatmenttime points, and increased in only one (Figures 2C and 2D; p =
0.002). In response to chemotherapy, Par-4 expression
decreased 1.7-fold across all tumors (Figure 2D) and 2.5-fold
for those tumors in which Par-4 mRNA levels declined following
treatment (data not shown). These results are consistent with a
model in which neoadjuvant chemotherapy selects for cancer
cells with low Par-4 expression.
Par-4 Downregulation Promotes Tumor Recurrence
The aforementioned observations raised the possibility that Par-
4 downregulation might play a functional role in breast cancer
recurrence by promoting tumor cell survival following therapy.
To test directly whether Par-4 downregulation promotes tumor
recurrence, we used an orthotopic mouse model to determine
the impact of Par-4 knockdown on the propensity of primary
HER2/neu-induced mammary tumors to recur.
Par-4 expression was suppressed in tumor cells cultured from
a primary HER2/neu-inducedmammary tumor (Prim 1) using ret-
rovirally delivered shRNAs. Two independent hairpins (Par-4.891
and Par-4.1011) were identified that suppressed Par-4 levels by
70%–80% to levels similar to those found in recurrent HER2/neu
tumor cells that had spontaneously downregulated Par-4 (Fig-
ure 3A). Control cells expressed an shRNA targeting Renilla lucif-
erase or an empty vector (MLP). Knocking down Par-4 did not
cause cells to undergo EMT, as assessed by the expression of
epithelial and mesenchymal markers (Figure S3A), further sug-
gesting that Par-4 functions independently of Snail and EMT.
Control and Par-4 knockdown primary tumor cells were in-
jected into the mammary fat pads of recipient nu/nu mice main-
tained on dox, and primary tumors were allowed to form in the
presence of HER2/neu expression. Par-4 knockdown and con-
trol tumors grew at similar rates (data not shown), suggesting
that Par-4 knockdown does not influence primary tumor forma-
tion. Once tumors had formed, dox was withdrawn to initiate
HER2/neu downregulation and tumor regression. All tumors re-
gressed to a nonpalpable state regardless of Par-4 knockdown30–44, July 8, 2013 ª2013 Elsevier Inc. 33
Figure 3. Par-4 Downregulation Is Neces-
sary and Sufficient for Tumor Recurrence
(A) Western analysis showing Par-4 expression in
control and Par-4 knockdown primary HER2/neu
tumor cells.
(B and C) RFS for mice harboring control tumors or
tumors expressing one of the two shRNAs tar-
geting Par-4.
(D) Western analysis showing Par-4 expression in
four control (MLP) recurrent orthotopic tumors.
(E) RFS for mice harboring control tumors or tu-
mors expressing a cDNA encoding Par-4.
(F) Western analysis showing endogenous (En-
dog.) and ectopic Par-4 expression in primary and
recurrent tumors.
See also Figure S3.
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mor recurrence.
Control tumors from Prim 1 cells recurred with a median la-
tency of 110 days (Figures 3B and 3C). In contrast, tumors ex-
pressing either of the two Par-4 shRNAs recurred 3–5 weeks
more rapidly than controls, with median latencies of 76 and
90 days (Figures 3B and 3C; HR = 2.4, 95% CI 1.6–8.7, p =
0.002 for Par-4.891; HR = 2.7, 95% CI 1.9–14.7, p = 0.002 for
Par-4.1011). Notably, as observed in intact MTB/TAN mice,
Par-4 was spontaneously downregulated in recurrent orthotopic
tumors that arose from control cells (Figure 3D).
In women with breast cancer, primary tumors with low Par-4
expression displayed poorer responses to chemotherapy than
tumors expressing higher levels of Par-4. To determine whether
this was also true in mice, we measured the extent of regression
of control and Par-4 knockdown tumors following oncogene
downregulation. This revealed that tumors with Par-4 knock-
down regressed to a lesser extent than control tumors
(Figure S3B).
Finally, to examine the effect of Par-4 knockdown on recur-
rence at distant sites, we analyzed lungs from these mice
because tumors in this model are known to recur in the lung.
Mice with recurrent tumors from Par-4 knockdown cells had
significantly more metastases than mice with control recurrent
tumors, suggesting that Par-4 downregulation also promotes
recurrence at distant sites (Figures S3C and S3D). Together,
these results provide direct functional evidence that Par-4 down-34 Cancer Cell 24, 30–44, July 8, 2013 ª2013 Elsevier Inc.regulation promotes mammary tumor
recurrence at both local and distant sites.
Par-4 Downregulation Is Required
for Tumor Recurrence
Our observations in mice that nearly all
recurrent mammary tumors downregu-
late Par-4 suggested that Par-4 downre-
gulation might be required for tumor
recurrence. To test this hypothesis, we
asked whether enforced expression of
Par-4 would delay tumor recurrence. A
second line of primary HER2/neu-
induced tumor cells (Prim 2) cultured
from tumor-bearing MTB/TAN mice wastransduced with a retrovirus expressing epitope-tagged Par-4
or a control vector, pK1. These cells were used in an orthotopic
recurrence assay to test the effect of forced Par-4 expression on
tumor recurrence.
Primary tumors expressing ectopic Par-4 grew at rates similar
to control tumors (data not shown), suggesting that Par-4
expression does not alter primary tumor growth. In contrast,
the latency for recurrence of tumors expressing ectopic Par-4
was delayed by 3 weeks compared to control tumors (Figure 3E,
median latency of 92 versus 70 days; HR = 0.34, 95% CI 0.07–
1.00; p = 0.05). As before, recurrent tumors arising from control
cells spontaneously downregulated endogenous Par-4 (Fig-
ure 3F). Strikingly, the majority of recurrent tumors arising from
Par-4-transduced primary tumor cells not only downregulated
endogenous Par-4 but also extinguished ectopic Par-4 expres-
sion (Figure 3F). These findings indicate that Par-4 downregula-
tion is required for mammary tumor recurrence and suggest the
existence of a strong selective pressure to downregulate both
endogenous and ectopically expressed Par-4 during the pro-
cess of recurrence.
Par-4 Is Upregulated following Oncogenic Pathway
Inhibition
In the aforementioned mouse models, tumor recurrence occurs
in discrete stages. First, tumors regress acutely in response to
oncogene downregulation as a consequence of increased
apoptosis and decreased cell proliferation. Thereafter, the small
Figure 4. Par-4 Is Upregulated following Oncogene Inhibition
(A) Western analysis of Par-4 following HER2/neu downregulation in primary tumor cells.
(B) Quantification of Par-4 levels from (A) normalized to tubulin.
(C) IF analysis of Par-4 in primary tumors (on dox; HER2/neu expressing) and tumors 3 or 7 days following HER2/neu downregulation. Scale bars, 50 mm.
(D) Western analysis of Par-4 in HER2-amplified human breast cancer cells treated with 100 nM lapatinib (Lap.).
(E) Quantification of Par-4 levels from (D) normalized to tubulin.
Error bars denote mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S4.
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histologically identifiable residual neoplastic lesion (data not
shown). Following a variable latent period, residual tumor cells
stochastically reinitiate growth to form recurrent tumors. Par-4
downregulation could occur anywhere along this process, and
its downregulation could functionally impact one or more stages
of recurrence.
To identify the stage of recurrence at which Par-4 is downre-
gulated, we first examined Par-4 expression shortly after onco-
gene downregulation in vitro. Prim 1 cells, derived from a primary
HER2/neu-induced tumor, were cultured in the presence of doxto maintain oncogene expression. Dox was then removed from
the media to initiate HER2/neu downregulation. Surprisingly,
HER2/neu downregulation led to a dramatic increase, rather
than decrease, in Par-4 expression beginning 48 hr following
dox withdrawal (Figures 4A and 4B). Furthermore, Par-4 levels
continued to increase for at least 7 days following dox with-
drawal. Par-4 expression was also upregulated in vivo following
acute HER2/neu (Figure 4C) or MYC downregulation (Figure S4).
We next wished to determine whether Par-4 upregulation
might be an evolutionarily conserved response to HER2/neu
inhibition in cancer cells. To address this, we treated twoCancer Cell 24, 30–44, July 8, 2013 ª2013 Elsevier Inc. 35
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Par-4 Inhibits Breast Cancer RecurrenceHER2/neu-amplified human breast cancer cell lines, BT-474 and
SKBR3, with the dual HER2/EGFR inhibitor lapatinib. In each cell
line, HER2/neu inhibition resulted in dramatic increases in Par-4
expression (Figures 4D and 4E). Together, these results indicate
that Par-4 levels increase, rather than decrease, following acute
oncogene inhibition in both mouse and human cancer cells, and
in vivo as well as in vitro.
Pre-Existing Cells with Low Par-4 Expression
Preferentially Survive Oncogene Downregulation
Our findings to this point suggested that oncogene inhibition and
chemotherapy might select for pre-existing cells with low Par-4
expression. We therefore asked whether a population of cells
with low Par-4 expression existed in primary tumors. Immunoflu-
orescence staining for Par-4 performed on primary HER2/neu
and Wnt1;p53+/ tumors revealed that whereas Par-4 was ex-
pressed at high levels throughout most of each primary tumor,
isolated regions exhibited low levels of Par-4 staining that were
comparable to levels found in recurrent tumors (Figures S5A
and S5B).
We previously reported that some primary Wnt1;p53+/
tumors fail to regress completely following Wnt1 downregula-
tion, suggesting that they have become Wnt independent (Gun-
ther et al., 2003). We considered the possibility that these
primary tumors have already downregulated Par-4. To address
this, we biopsied a cohort of primary Wnt1;p53+/ tumors and
then removed dox to induce tumor regression. As previously re-
ported, some tumors failed to regress following Wnt downregu-
lation, whereas others regressed to a nonpalpable state.We then
compared Par-4 expression levels in biopsies from primary tu-
mors that ultimately regressed completely following oncogene
downregulation with biopsies from primary tumors that did not.
As predicted, Par-4 levels were lower in primary tumors that
did not regress completely following Wnt1 downregulation
compared to primary tumors that did (Figures S5C and S5D).
This provides further evidence that primary tumor cells
with low Par-4 expression preferentially survive oncogene
downregulation.
To test directly whether pre-existing primary tumor cells with
low Par-4 expression preferentially survive HER2/neu downre-
gulation, we asked whether cells in which Par-4 had been
knocked down exhibit a survival advantage following HER2/
neu downregulation in vivo and are thereby selected for in resid-
ual lesions. We performed a cellular competition assay in which
GFP-labeled HER2/neu Prim 1 tumor cells expressing a Par-4
shRNA were admixed in a 1:1 ratio with isogenic mCherry-
labeled primary tumor cells expressing a control shRNA target-
ing Renilla luciferase. Cells were injected into the mammary fat
pads of recipient nu/numice maintained on dox. Primary tumors
were harvested from one cohort of mice, and dox waswithdrawn
from a second cohort to induce tumor regression. Twenty-eight
days later, mammary glands bearing residual tumor cells were
harvested, and the ratio of GFP:mCherry-labeled tumor cells in
residual lesions was assessed by fluorescence microscopy.
In primary tumors, the ratio of GFP-labeled Par-4 knockdown
cells to mCherry-labeled control cells was approximately 1:1,
confirming that Par-4 knockdown does not confer a selective
advantage during primary tumor formation in the presence of
HER2/neu expression (Figures 5A and 5B). In contrast, cells36 Cancer Cell 24, 30–44, July 8, 2013 ª2013 Elsevier Inc.with Par-4 knockdown constituted 80%–90% of the tumor cells
present within residual lesions (Figures 5A and 5B).
We next asked whether Par-4 knockdown also confers a sur-
vival advantage in vitro following HER2/neu downregulation us-
ing a similar cell competition assay. In the presence of HER2/
neu expression, cells maintained an 1:1 ratio over the course
of 10 days (data not shown). In contrast, selection for Par-4
knockdown cells was evident within 5 days following HER2/
neu downregulation, and within 14 days, these cells were pre-
dominant (Figure 5C). The ratio of control GFP- to control
mCherry-labeled cells did not change in the presence or
absence of dox (Figure 5C; data not shown).
Together, these results demonstrate that Par-4 downregula-
tion confers a selective, cell-intrinsic advantage to tumor cells
following HER2/neu downregulation. Furthermore, these find-
ings confirmed our prediction that pre-existing primary tumor
cells with low Par-4 expression preferentially survive oncogene
downregulation. This, in turn, suggests that Par-4 downregula-
tion promotes recurrence by facilitating tumor cell survival
following treatment with antineoplastic agents.
Par-4 Downregulation Promotes Tumor Cell Survival
following Oncogene Inhibition
HER2/neu downregulation in mouse mammary tumors results in
apoptosis as a consequence of oncogene addiction (Moody
et al., 2002). Because the increase in apoptosis following
HER2/neu downregulation is accompanied by increased expres-
sion of the proapoptotic protein Par-4, and because cells with
Par-4 knockdown are selected for following HER2/neu downre-
gulation in vivo, we reasoned that Par-4 upregulation may
contribute to cell death following oncogene inhibition.
To address this possibility, we measured the viability of HER2/
neu-dependent primary tumor cells, with or without Par-4
knockdown, 4 days following HER2/neu downregulation.
HER2/neu downregulation resulted in a 15% absolute increase
in cell death in control cells, whereas only an 5% increase in
cell death was observed in Par-4 knockdown cells generated
using two different hairpins (Figure 5D; p < 0.05). Importantly,
whereas the level of Par-4 increased following HER2/neu down-
regulation in cells expressing Par-4 shRNAs, Par-4 levels re-
mained lower than in control cells expressing HER2/neu (Figures
S5E and S5F). Because primary tumor cells expressing HER2/
neu tolerate basal levels of Par-4, these findings suggest that
Par-4 upregulation above this basal level may contribute to
cell death.
To determine the impact of Par-4 downregulation on longer-
term measures of cell survival following HER2/neu downregula-
tion, we measured the effect of Par-4 knockdown on clonogenic
survival following dox withdrawal. In the presence of dox, control
cells and Par-4 knockdown cells formed colonies with similar ef-
ficiency (Figure 5E, top row). However, when grown in the
absence of dox for 3 weeks, cells expressing a Par-4 shRNA
formed 8- to 21-fold more colonies than control cells (Figures
5E and 5F; p < 0.001). Dox was added back to a subset of plates
for 1 week to reinduce oncogene expression in any cells that had
survived HER2/neu downregulation. Again, cells expressing
either of the two Par-4 shRNAs formed a greater number of col-
onies than control cells, and their mean size was larger (Figures
5E and 5F).
Figure 5. Par-4 Downregulation Promotes Survival following Oncogene Withdrawal
(A) Fluorescent micrographs from an in vivo competition assay showing primary tumors and residual lesions formed from injecting a 1:1 mixture of GFP- and
mCherry-labeled control cells (MLP +MLP-Red) or a 1:1 mixture of GFP-labeled Par-4 knockdown cells andmCherry-labeled control cells (Par-4.891 +MLP Red
and Par-4.1011 + MLP-Red). Scale bars, 50 mm.
(B) Quantification of the relative proportion of GFP+ and mCherry+ cells in primary tumors or residual lesions.
(C) Control (MLP) or Par-4 knockdown (Par-4.891 or Par-4.1011) cells labeled with GFP were mixed in a 1:1 ratio with control cells labeled with mCherry (MLP-
Red), and the relative proportion of green to red cells was measured by flow cytometry following HER2/neu downregulation in vitro.
(D) Percent increase in nonviable cells following HER2/neu downregulation in primary tumor cells expressing a control vector (MLP) or one of the two shRNAs
targeting Par-4.
(E) Clonogenic survival of cells of the indicated genotype grown in the presence of HER2/neu (+dox) or in the absence of HER2/neu (dox) for 3 weeks. Dox was
added back to a subset of plates for 1 week to reinduce HER2/neu expression (dox/ +dox).
(F) Quantification of the surviving colonies in (E).
Error bars denote mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S5.
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Figure 6. Reexpressing Par-4 in Recurrent Tumor Cells Induces Multinucleation Accompanied by p53 Activation, Growth Arrest, and
Apoptosis
(A) Cell viability was measured following retroviral transduction of Par-4 into primary or recurrent cells.
(B) Western analysis showing Par-4 expression following Shld-1 treatment of recurrent tumor cells expressing L106P-Par-4 constructs.
(C) Growth curves of vehicle or Shld-1-treated control cells (L106P-YFP or Luc-L106P) or Par-4-inducible cells (L106P-Par-4).
(legend continued on next page)
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mor cells from cell death induced by chemotherapeutic agents.
Control or Par-4 knockdown cells were treated with etoposide,
vincristine, or Adriamycin for 4 days, and cell viability was
measured. Par-4 knockdown increased the fractionof cells surviv-
ing each treatment by 20%–40% (Figure S5G), confirming that
Par-4 downregulation protects cells from chemotherapy-induced
cell death. Together, these results demonstrate that Par-4 down-
regulation promotes cell survival following antineoplastic therapy,
thereby providing a mechanistic explanation for the observations
that cells with Par-4 knockdown are selected for following onco-
gene downregulation and are more likely to recur.
Par-4 Induces Multinucleation and Cell Death in
Recurrent Tumor Cells
Our findings to this point demonstrated that Par-4 is acutely up-
regulated following HER2/neu inhibition and that pre-existing
cells with low Par-4 expression preferentially survive tumor
regression induced by oncogene downregulation. These obser-
vations suggested that cells in which Par-4 is upregulated in
response to HER2/neu inhibition might be selected against dur-
ing tumor regression and, in a related manner, that elevated Par-
4 expression in recurrent tumor cells might be incompatible with
cell survival.
To address this question, we investigated the consequences
of reexpressing Par-4 in recurrent tumor cells that had spontane-
ously downregulated endogenous Par-4. Independent cell lines
were generated from two recurrent tumors that arose in MTB/
TANmice. As predicted, Par-4 expression was lower in recurrent
compared to primary tumor cell lines (Figure S6A). Ectopic
expression of Par-4 by retroviral transduction of each of these
recurrent cell lines induced high levels of cell death (Figure 6A).
In contrast, ectopic expression of Par-4 in primary HER2/neu-
expressing tumor cells resulted in only a modest increase in
cell death (Figure 6A). These results suggest that high Par-4
expression is incompatible with the survival of recurrent, but
not primary, tumor cells and are consistent with amodel in which
Par-4 downregulation is required for the survival of cells in which
the HER2/neu pathway has been inhibited.
To avoid artifacts due to the expression of nonphysiological
levels of Par-4, we titrated the levels of ectopically expressed
Par-4 in recurrent tumor cells to those observed in primary tumor
cells following acute oncogene downregulation using an induc-
ible system comprised of a mutant FKBP domain (L106P) and
its synthetic ligand Shld-1 (Banaszynski et al., 2006). Treatment
of recurrent tumor cell lines expressing an L106P-Par-4 fusion
protein with 1 mM Shld-1 yielded Par-4 levels comparable to
those observed in primary tumor cells following HER2/neu
downregulation (Figures S6B and S6C). Shld-1 induction of
Par-4 in L106P-Par-4-expressing recurrent tumor cell lines led(D) Recurrent tumor cells were treated with Shld-1 for 24 hr and visualized by ligh
Arrows indicate multinucleated cells.
(E) Quantification of multinucleated cells following 24 hr Shld-1 treatment.
(F) IF staining for p53 in multinucleated cells following Shld-1 treatment.
(G) IF analysis of BrdU incorporation in multinucleated and control cells following
(H) Quantification of percentage of BrdU+ cells corresponding to the experiment
(I) IF staining for cleaved caspase-3 in multinucleated cells following Shld-1 trea
Scale bars, 50 mm. Error bars denote mean ± SEM. *p < 0.05; **p < 0.01; ***p <
See also Figure S6.to a profound reduction in their growth rates (Figures 6B and
6C). Shld-1 had no effect on the growth rates of control tumor
cells expressing L106P-YFP or Luc-L106P fusion proteins
(Figure 6C).
Strikingly, visual examination of recurrent cells following Shld-
1 treatment for 24 hr revealed large numbers of multinucleated
cells (Figure 6D). Multinucleated cells appeared as early as 6 hr
following Shld-1 treatment (data not shown) and constituted
15%–20% of all cells within 24 hr (Figure 6E). Multinucleated
cells were also observed in cells transduced with wild-type
Par-4 (i.e., not fused to L106P), but not in Shld-1-treated control
cells (data not shown). This indicates that multinucleated cells
arise as a consequence of Par-4 expression rather than Shld-1
administration or L106P-fusion protein expression.
Multinucleated cells have a tetraploid DNA content, and tetra-
ploid cells reportedly undergo p53-dependent cell-cycle arrest
and death (Andreassen et al., 2001; Margolis et al., 2003). To
address the fate of multinucleated cells, we treated recurrent tu-
mor cells with Shld-1 for 4 days and analyzed p53 expression,
BrdU incorporation, and cleaved caspase-3 staining.Multinucle-
ated cells in Par-4-expressing cultures exhibited robust nuclear
p53 staining, whereas control cells did not (Figure 6F), suggest-
ing that Par-4-induced multinucleation engenders a p53
response. Multinucleated cells exhibited a 50% lower rate of
proliferation than control cells (Figures 6G and 6H), and multinu-
cleated cells induced by retroviral transduction of Par-4 (Fig-
ure 6I, top) or Shld-1 treatment (Figure 6I, bottom) stained
strongly positive for cleaved caspase-3, indicating that they
were undergoing apoptosis.
To determine whether Par-4-dependent growth arrest and
apoptosis are p53 dependent, we knocked down p53 in recur-
rent cells (Figure S6D) and measured the number of viable cells
4 days following Shld-1 treatment. The decrease in cell viability
induced by Par-4 was partially rescued by p53 knockdown (Fig-
ure S6E). Similarly, p53 knockdown increased the clonogenic
survival of cells following Par-4 induction by Shld1 treatment
(Figure S6F). Together, these results indicate that p53 mediates
some, but likely not all, of the antiproliferative and proapoptotic
effects of restoring Par-4 expression in recurrent tumor cells.
These findings demonstrate that restoring Par-4 expression in
recurrent tumor cells results in the formation of multinucleated
cells that undergo p53 activation, growth arrest, and apoptosis.
This, in turn, suggests a mechanism selecting against cells that
have upregulated Par-4 in response to inhibition of an oncogenic
pathway to which they had become addicted.
Par-4 Induces Multinucleation through ZIPK-Mediated
MLC2 Phosphorylation and Cytokinesis Failure
To determine the mechanism by which Par-4 causes multinu-
cleation, we performed live-cell imaging on cells treated witht microscopy or fluorescence microscopy following immunostaining for Par-4.
Shld-1 treatment.
shown in (G).
tment or retroviral transduction of Par-4 in recurrent cells.
0.001.
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Figure 7. Par-4 Causes Cytokinesis Failure through ZIPK-Mediated MLC2 Phosphorylation
(A) Stills from live-cell imaging of recurrent tumor cells expressing H2B-mCherry and L106P-Par-4 untreated (top row) or treated with Shld-1 (bottom row). Scale
bars, 15 mm.
(B) Western analysis showing p-MLC2 levels following retroviral transduction of Par-4 into recurrent tumor cells.
(C) IF analysis showing p- MLC2 following Shld-1 treatment of recurrent cells expressing L106P-Par-4. Scale bars, 10 mm.
(D) Quantitative reverse-transcription PCR showing ZIPK expression following transfection of recurrent cells with a control pool or an siRNA pool targeting ZIPK.
(E) Western analysis of p-MLC2 levels in ZIPK knockdown cells 24 hr after Par-4 expression.
(F) Quantification of the percentage of multinucleated cells 24 hr after Par-4 expression in control and ZIPK knockdown cells.
Error bars denote mean ± SEM. *p < 0.05.
See also Movies S1 and S2.
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proceeded normally giving rise to two daughter cells with one nu-
cleus each (Figure 7A, top; Movie S1). In contrast, cells treated
with Shld-1 underwent aberrant mitoses that often failed during
cytokinesis (Figure 7A, bottom; Movie S2). These cells pro-
gressed normally through metaphase, anaphase, and initial
ingression of the cleavage furrow. However, during later stages
of cleavage furrow ingression, Par-4-expressing cells underwent
dramatic blebbing that was ultimately accompanied by regres-
sion of the cleavage furrow, yielding a binucleated cell (Figure 7A;
Movie S2). Cytokinesis failure occurred during the first mitosis
following Shld-1 treatment, consistent with Par-4-induced cyto-
kinesis failure being a direct effect rather than a secondary
consequence of cell stress or growth arrest.
To elucidate the molecular mechanism by which Par-4 causes
cytokinesis failure, we evaluated ZIP kinase (ZIPK) and its sub-
strate myosin light-chain 2 (MLC2). Par-4 has been shown to40 Cancer Cell 24, 30–44, July 8, 2013 ª2013 Elsevier Inc.induce MLC2 phosphorylation through activation of ZIPK, and
this pathway has been implicated in the regulation of cell
contractility and cell death (Boosen et al., 2009; Page et al.,
1999; Vetterkind et al., 2005; Vetterkind and Morgan, 2009).
MLC2 phosphorylation is also required for cytokinesis because
phosphorylation of MLC2 on threonine 18 and serine 19 acti-
vates myosin II and promotes furrow ingression (Matsumura,
2005). Conversely, increased MLC2 phosphorylation, which
may occur through depletion of myosin phosphatase (MYPT1),
results in cytokinesis defects in C. elegans (Piekny and Mains,
2002) as well as mammalian cells (Yamashiro et al., 2008). These
observations suggest that cytokinesis requires tightly regulated
levels of MLC2 phosphorylation.
We hypothesized that Par-4 upregulation may induce cytoki-
nesis failure by dysregulatingMLC2 phosphorylation. Consistent
with this possibility, retroviral expression of Par-4 in recurrent
tumor cells led to an increase in MLC2 phosphorylation
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Par-4 Inhibits Breast Cancer Recurrence(Figure 7B), and multinucleated cells induced by Shld-1 treat-
ment exhibited high levels of pMLC2 (Figure 7C).
To determine whether Par-4-induced cytokinesis failure re-
quires ZIPK, we examined the effect of ZIPK knockdown on
Par-4-induced multinucleation. Transfection of recurrent tumor
cells with an siRNA targeting ZIPK led to an 60% reduction
in ZIPK levels compared to control cells (Figure 7D). Control
and ZIPK knockdown cells were treated with Shld-1 to induce
Par-4 expression, and the fraction of multinucleated cells was
determined after 24 hr. ZIPK knockdown abrogated Par-4-
inducedMLC2 phosphorylation (Figure 7E) and led to a dramatic
reduction in Par-4-induced multinucleation (Figure 7F). These
results suggest that Par-4 induces multinucleation through a
ZIPK-dependent increase in MLC2 phosphorylation that dis-
rupts the precise temporal and spatial control of MLC2 phos-
phorylation that is required for the successful completion of
cytokinesis.
HER2/neu Inhibition Induces Par-4-Dependent
Multinucleation in Mouse and Human Cancer Cells
Re-expression of Par-4 in recurrent tumor cells that do not ex-
press HER2/neu results in multinucleation, apoptosis, and
reduced proliferation. In an analogousmanner, HER2/neu down-
regulation in primary tumor cells is accompanied by Par-4 upre-
gulation, apoptosis, and growth arrest. This suggested that the
increased apoptosis and growth arrest observed in primary tu-
mor cells following acute HER2/neu downregulation might be
mediated, in part, by Par-4-induced multinucleation. We there-
fore asked whether primary tumor cells become multinucleated
following HER2/neu downregulation.
Dox withdrawal induced a 2-fold increase in the percentage of
multinucleated cells in two independent cultures of primary
HER2/neu tumor-derived cells (Figures 8A and 8B). Multinuclea-
tion was dependent upon Par-4 because cells expressing either
of the two shRNAs targeting Par-4 failed to become multinucle-
ated following dox withdrawal (Figure 8C).
We next examined whether human breast cancer cells also
become multinucleated following HER2/neu inhibition. Treat-
ment of HER2-amplified BT474 cells with lapatinib led to a
dose-dependent increase in polyploid cells (Figure 8D). More-
over, analogous to our observations in mouse tumor cells, the
lapatinib-induced increase in polyploid BT474 cells was depen-
dent upon Par-4 because cells expressing an shRNA targeting
Par-4 failed to become polyploid following HER2/neu inhibition
(Figure 8D).
Finally, we askedwhether Par-4 upregulation andmultinuclea-
tion also occur in response to treatment with chemotherapeutic
agents. Treatment with low-dose Adriamycin has been reported
to inducemultinucleation in certain breast cancer cell lines (Man-
silla et al., 2006). Therefore, we determined whether multinuclea-
tion in this context was accompanied by Par-4 upregulation.
Treatment of MDA-MB-231 cells with Adriamycin induced poly-
ploidy (Figure S7A). Interestingly, whereas total Par-4 levels were
unchanged, Adriamycin treatment led to an increase in phos-
phorylation of T163 of Par-4 (Figure S7B), a phosphorylation
event that is required for Par-4-induced apoptosis (Gurumurthy
et al., 2005). Our results reveal that a chemotherapeutic agent
that induces multinucleation also leads to Par-4 activation
through phosphorylation on a conserved threonine residue. Inaggregate, our findings suggest that treatment of human and
mouse cancer cells with targeted agents or chemotherapeutic
agents results in Par-4-dependent multinucleation and cell
death.
DISCUSSION
We have identified the proapoptotic tumor suppressor protein
Par-4 as a critical negative regulator of mammary tumor recur-
rence. Par-4 expression is spontaneously downregulated in
recurrent tumors arising in mice bearing fully regressed HER2/
neu, MYC, or Wnt1;p53+/-induced mammary tumors. Par-4
knockdown accelerated tumor recurrence, whereas enforced
expression of Par-4 delayed recurrence, indicating that Par-4
downregulation is both necessary and sufficient to promote
mammary tumor recurrence. Furthermore, we found that pre-
existing cells with low Par-4 expression preferentially survive
oncogene downregulation in vivo and in vitro. Finally, we defined
the mechanistic basis for the preferential survival of low Par-4-
expressing cancer cells as resulting from the fact that HER2/
neu inhibition results in Par-4 upregulation that is accompanied
by Par-4-dependent multinucleation, growth arrest, and
apoptosis. These findings provide a mechanistic link between
Par-4, oncogene addiction and the suppression of tumor
recurrence.
Consistent with our findings in mice, our studies also revealed
that low Par-4 expression is associated with an elevated risk of
recurrence in womenwith breast cancer. Although Par-4 expres-
sion is associated with aggressive subsets of human breast
cancers, including ER, basal-like, and high-grade tumors,
multivariate analysis revealed that the association of low Par-4
expression with increased risk of recurrence is independent of
each of these variables, suggesting that Par-4 downregulation
may mediate at least some aspects of the aggressive biological
behavior of these subtypes.
Additional mechanistic insights into the association between
low Par-4 expression and poor prognosis in women with breast
cancer were garnered from the I-SPY 1 neoadjuvant chemo-
therapy trial, which suggested that Par-4 downregulation
enhances the ability of tumors cells to survive chemotherapy. Tu-
mors that responded poorly to neoadjuvant chemotherapy
exhibited significantly lower Par-4 expression prior to chemo-
therapy than tumors that respondedwell, indicating that the level
of Par-4 expression in a tumor prior to treatment predicts that tu-
mor’s response to chemotherapy. This, in turn, raises the
intriguing possibility that Par-4 may be a determinant of that
response.
Consistent with the finding that low Par-4 expression is asso-
ciated with decreased RFS in women with breast cancer, and
that low Par-4-expressing cancer cells in mice preferentially sur-
vive treatment with chemotherapeutic or targeted agents, we
found that residual breast cancer cells in patients treated with
neoadjuvant chemotherapy in the I-SPY 1 TRIAL downregulated
Par-4. This suggests that chemotherapy selects for pre-existing
cells within primary tumors that express low levels of Par-4.
In aggregate, our data suggest a two-step model in which
cells that upregulate Par-4 following acute oncogene in-
hibition are selected against or are otherwise eliminated
by Par-4-dependent multinucleation, growth arrest, andCancer Cell 24, 30–44, July 8, 2013 ª2013 Elsevier Inc. 41
Figure 8. Oncogene Inhibition Leads to Par-4-Dependent Multinucleation
(A) Photomicrographs of cells following HER2/neu downregulation in primary MTB/TAN tumor cells. Arrows indicate multinucleated cells. Scale bars, 50 mm.
(B) Quantification of percentage of multinucleated cells corresponding to the experiment shown in (A).
(C) Percentage of multinucleated control or Par-4 knockdown MTB/TAN cells following HER2/neu downregulation.
(D) Percentage of control or Par-4 knockdown BT-474 cells with polyploid DNA content following lapatinib treatment as measured by flow cytometry.
(E) Model for the role of Par-4 downregulation in tumor recurrence. Oncogene inhibition or chemotherapy results in Par-4-dependent multinucleation, which in
turn leads to p53 activation, growth arrest, and apoptosis. Together, these cellular processes contribute to tumor regression, such that cells surviving tumor
regression exhibit spontaneous Par-4 downregulation. These cells ultimately give rise to recurrent tumors with low Par-4 expression.
Error bars denote mean ± SEM. *p < 0.05; **p < 0.01.
See also Figure S7.
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sion in the face of oncogene inhibition are selected for during
tumor regression, and recurrent tumors arising from this popula-
tion of cells express low levels of Par-4 (Figure 8E). Par-4 expres-42 Cancer Cell 24, 30–44, July 8, 2013 ª2013 Elsevier Inc.sion in primary tumors is heterogeneous, with most cells
expressing Par-4 but some expressing lower levels. Treatment
of tumors—either through blockade of a dominant oncogenic
pathway or treatment with conventional chemotherapeutic
Cancer Cell
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upregulation of Par-4 protein levels. Par-4 activation, in turn,
results in multinucleation, p53 stabilization, decreased prolifera-
tion, and increased apoptosis, which together contribute to tu-
mor regression. In this manner, treatment with antineoplastic
agents selects for cancer cells that have downregulated Par-4,
as we observed in residual cancer cells in patients with breast
cancer following chemotherapy and tumor regression. Because
these residual cells ultimately serve as the reservoir from which
recurrent tumors arise, recurrent tumors express low levels of
Par-4.
As a corollary to this model, we hypothesize that the level of
Par-4 expression observed in primary human breast cancers re-
flects, at least in part, the fraction of Par-4-expressing tumor
cells contained within that cancer. As such, breast cancers ex-
hibiting low Par-4 expression may contain a high proportion of
cells in which Par-4 has been downregulated, a greater number
of cancer cells that survive chemotherapy, a higher RCB, and ul-
timately, an increased rate of tumor recurrence. This, in turn,
would explain the spontaneous downregulation of Par-4 that
we observed in recurrent mammary tumors in mice, the ability
of Par-4 knockdown to accelerate tumor recurrence in mice,
the decrease in Par-4 expression observed in women treated
with neoadjuvant chemotherapy in the I-SPY 1 TRIAL, and the
association between low Par-4 expression and decreased RFS
in women with breast cancer.
Our studies have also identified the induction of multinuclea-
tion as a mechanism of cell death following the blockade of a
dominant oncogenic pathway in tumor cells. Specifically, our
findings reveal that Par-4 re-expression in recurrent cells results
in cytokinesis failure through increased MLC2 phosphorylation
and that this requires ZIPK activity. Multinucleated cells possess
a tetraploid DNA content, and a ‘‘tetraploid checkpoint’’ has
been proposed that induces cell-cycle arrest and apoptosis in
response to an abnormal complement of chromosomes during
the G1 phase of the cell cycle (Andreassen et al., 2001; Margolis
et al., 2003). Although the existence of this checkpoint remains
controversial, it is clear that mechanisms exist that limit the pro-
liferation and survival of tetraploid cells (Castedo et al., 2006;
Ganem and Pellman, 2007; Ganem et al., 2007). Moreover, this
response likely requires an intact p53 pathway because the in-
duction of tetraploidy in a p53-deficient background is tumori-
genic (Fujiwara et al., 2005). This suggests that an intact p53
pathway limits the survival of tetraploid cells and that induction
of tetraploidy in cells with functional p53may be antitumorigenic,
rather than protumorigenic. Consistent with this, we observed
p53 stabilization in multinucleated cells following Par-4 expres-
sion. These results demonstrate that induction of tetraploidy
can serve as a mechanism for eliminating oncogene-addicted
cells or, more generally, as a mechanism of tumor suppression.
Our results demonstrate that Par-4-dependent multinuclea-
tion induced by HER2/neu inhibition represents a pathway by
which oncogene-addicted cells are selected against following
oncogene downregulation. Cancer recurrence requires that the
tumor-suppressive effects of multinucleation be circumvented
via downregulation of Par-4. Therapeutic approaches that
restore Par-4 expression in tumors that have downregulated
this tumor suppressor protein may enhance the therapeutic
response to targeted agents as well as chemotherapy. Further-more, because Par-4 expression is incompatible with the sur-
vival of recurrent cancer cells, restoring Par-4 expression in
dormant cancer cells or recurrent cancers may constitute an
effective approach to preventing, or treating, this fatal stage of
cancer progression.
EXPERIMENTAL PROCEDURES
Animals and Orthotopic Recurrence Assays
Animal care and experiments were performed with the approval of, and in
accordance with, guidelines of the University of Pennsylvania IACUC. Details
of tumor generation, orthotopic recurrence assays, and competition assays
are provided in Supplemental Experimental Procedures.
Human Subjects
The I-SPY 1 TRIAL was a collaboration of the American College of Radiology
Imaging Network (ACRIN), Cancer and Leukemia Group B (CALGB), and the
National Cancer Institute (NCI)’s Specialized Programs of Research Excel-
lence. It consisted of two protocols developed to identify markers of response
to conventional neoadjuvant chemotherapy: CALGB 150007 (molecular
marker component), and ACRIN 6657/CALGB 150012 (imaging component).
The protocol was approved by institutional review boards at all participating
institutions. Patients signed one combined informed consent form before
joining the study, which allowed them to simultaneously enroll in the CALGB
and ACRIN protocols.
Tissue Culture, Plasmids, and RNAi
Primary and recurrentMTB/TAN primary tumor cells were grown as described
byMoody et al. (2005). Additional information on in vitro assays, plasmids, and
RNAi is provided in Supplemental Experimental Procedures.
Immunoblotting, Immunofluorescence, Quantitative Reverse-
Transcription PCR, Microscopy, and Flow Cytometry
Immunoblotting and immunofluorescence were performed as described by
Moody et al. (2005). Information on antibodies, and descriptions of experi-
mental procedures for quantitative reverse-transcription PCR, live-cell imag-
ing, and flow cytometry are presented in Supplemental Experimental
Procedures.
Human Breast Cancer Data Sets
Publicly available microarray data for human primary breast cancer data sets
and their corresponding clinical annotation were downloaded and, where
necessary, converted to log2 scale. Details on data sets and methods for sur-
vival and multivariate analysis are provided in Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, five tables, and two movies and can be found with this article
online at http://dx.doi.org/10.1016/j.ccr.2013.05.007.
ACKNOWLEDGMENTS
We thank the Cancer and Leukemia Group B (Alliance) for providing clinical
data from the I-SPY 1 clinical trial and Laura Esserman, Dan Sargent, Edith
Perez, and Sherry Breaux for helpful comments on the manuscript. We thank
Eric Witze for assistance with time-lapse microscopy. This work was sup-
ported by grants from the National Institutes of Health, the Department of De-
fense Breast Cancer Research Program, and the Breast Cancer Research
Foundation.
Received: October 2, 2012
Revised: March 11, 2013
Accepted: May 9, 2013
Published: June 13, 2013Cancer Cell 24, 30–44, July 8, 2013 ª2013 Elsevier Inc. 43
Cancer Cell
Par-4 Inhibits Breast Cancer RecurrenceREFERENCES
Andreassen, P.R., Lohez, O.D., Lacroix, F.B., and Margolis, R.L. (2001).
Tetraploid state induces p53-dependent arrest of nontransformedmammalian
cells in G1. Mol. Biol. Cell 12, 1315–1328.
Banaszynski, L.A., Chen, L.C., Maynard-Smith, L.A., Ooi, A.G., andWandless,
T.J. (2006). A rapid, reversible, and tunablemethod to regulate protein function
in living cells using synthetic small molecules. Cell 126, 995–1004.
Bednarz-Knoll, N., Alix-Panabie`res, C., and Pantel, K. (2011). Clinical rele-
vance and biology of circulating tumor cells. Breast Cancer Res. 13, 228.
Boosen, M., Vetterkind, S., Kubicek, J., Scheidtmann, K.H., Illenberger, S.,
and Preuss, U. (2009). Par-4 is an essential downstream target of DAP-like ki-
nase (Dlk) in Dlk/Par-4-mediated apoptosis. Mol. Biol. Cell 20, 4010–4020.
Boxer, R.B., Jang, J.W., Sintasath, L., and Chodosh, L.A. (2004). Lack of sus-
tained regression of c-MYC-induced mammary adenocarcinomas following
brief or prolonged MYC inactivation. Cancer Cell 6, 577–586.
Castedo, M., Coquelle, A., Vivet, S., Vitale, I., Kauffmann, A., Dessen, P.,
Pequignot, M.O., Casares, N., Valent, A., Mouhamad, S., et al. (2006).
Apoptosis regulation in tetraploid cancer cells. EMBO J. 25, 2584–2595.
D’Cruz, C.M., Gunther, E.J., Boxer, R.B., Hartman, J.L., Sintasath, L., Moody,
S.E., Cox, J.D., Ha, S.I., Belka, G.K., Golant, A., et al. (2001). c-MYC induces
mammary tumorigenesis by means of a preferred pathway involving sponta-
neous Kras2 mutations. Nat. Med. 7, 235–239.
Diaz-Meco, M.T., and Abu-Baker, S. (2009). The Par-4/PTEN connection in tu-
mor suppression. Cell Cycle 8, 2518–2522.
Dı´az-Meco, M.T., Municio, M.M., Frutos, S., Sanchez, P., Lozano, J., Sanz, L.,
and Moscat, J. (1996). The product of par-4, a gene induced during apoptosis,
interacts selectively with the atypical isoforms of protein kinase C. Cell 86,
777–786.
Esserman, L.J., Berry, D.A., Cheang, M.C., Yau, C., Perou, C.M., Carey, L.,
Demichele, A., Gray, J.W., Conway-Dorsey, K., Lenburg, M.E., et al. (2012).
Chemotherapy response and recurrence-free survival in neoadjuvant breast
cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL
(CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 132,
1049–1062.
Fujiwara, T., Bandi, M., Nitta, M., Ivanova, E.V., Bronson, R.T., and Pellman, D.
(2005). Cytokinesis failure generating tetraploids promotes tumorigenesis in
p53-null cells. Nature 437, 1043–1047.
Ganem, N.J., and Pellman, D. (2007). Limiting the proliferation of polyploid
cells. Cell 131, 437–440.
Ganem, N.J., Storchova, Z., and Pellman, D. (2007). Tetraploidy, aneuploidy
and cancer. Curr. Opin. Genet. Dev. 17, 157–162.
Gunther, E.J., Moody, S.E., Belka, G.K., Hahn, K.T., Innocent, N., Dugan, K.D.,
Cardiff, R.D., and Chodosh, L.A. (2003). Impact of p53 loss on reversal and
recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. 17,
488–501.
Gurumurthy, S., Goswami, A., Vasudevan, K.M., and Rangnekar, V.M. (2005).
Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol. Cell.
Biol. 25, 1146–1161.
Mansilla, S., Priebe, W., and Portugal, J. (2006). Mitotic catastrophe results in
cell death by caspase-dependent and caspase-independent mechanisms.
Cell Cycle 5, 53–60.
Margolis, R.L., Lohez, O.D., and Andreassen, P.R. (2003). G1 tetraploidy
checkpoint and the suppression of tumorigenesis. J. Cell. Biochem. 88,
673–683.44 Cancer Cell 24, 30–44, July 8, 2013 ª2013 Elsevier Inc.Matsumura, F. (2005). Regulation of myosin II during cytokinesis in higher eu-
karyotes. Trends Cell Biol. 15, 371–377.
Me´ndez-Lo´pez, L.F., Zapata-Benavides, P., Zavala-Pompa, A., Aguado-
Barrera, M.E., Pacheco-Calleros, J., Rodrı´guez-Padilla, C., Cerda-Flores,
R.M., Corte´s-Gutie´rrez, E.I., and Da´vila-Rodrı´guez, M.I. (2010).
Immunohistochemical analysis of prostate apoptosis response-4 (Par-4) in
Mexican women with breast cancer: a preliminary study. Arch. Med. Res.
41, 261–268.
Moody, S.E., Sarkisian, C.J., Hahn, K.T., Gunther, E.J., Pickup, S., Dugan,
K.D., Innocent, N., Cardiff, R.D., Schnall, M.D., and Chodosh, L.A. (2002).
Conditional activation of Neu in the mammary epithelium of transgenic mice
results in reversible pulmonary metastasis. Cancer Cell 2, 451–461.
Moody, S.E., Perez, D., Pan, T.C., Sarkisian, C.J., Portocarrero, C.P., Sterner,
C.J., Notorfrancesco, K.L., Cardiff, R.D., and Chodosh, L.A. (2005). The tran-
scriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell
8, 197–209.
Nagai, M.A., Gerhard, R., Salaorni, S., Fregnani, J.H., Nonogaki, S., Netto,
M.M., and Soares, F.A. (2010). Down-regulation of the candidate tumor sup-
pressor gene PAR-4 is associated with poor prognosis in breast cancer. Int.
J. Oncol. 37, 41–49.
Page, G., Ko¨gel, D., Rangnekar, V., and Scheidtmann, K.H. (1999). Interaction
partners of Dlk/ZIP kinase: co-expression of Dlk/ZIP kinase and Par-4 results
in cytoplasmic retention and apoptosis. Oncogene 18, 7265–7273.
Piekny, A.J., andMains, P.E. (2002). Rho-binding kinase (LET-502) andmyosin
phosphatase (MEL-11) regulate cytokinesis in the early Caenorhabditis
elegans embryo. J. Cell Sci. 115, 2271–2282.
Ranganathan, P., and Rangnekar, V.M. (2005). Regulation of cancer cell sur-
vival by Par-4. Ann. N Y Acad. Sci. 1059, 76–85.
Saphner, T., Tormey, D.C., and Gray, R. (1996). Annual hazard rates of recur-
rence for breast cancer after primary therapy. J. Clin. Oncol. 14, 2738–2746.
Sells, S.F., Wood, D.P., Jr., Joshi-Barve, S.S., Muthukumar, S., Jacob, R.J.,
Crist, S.A., Humphreys, S., and Rangnekar, V.M. (1994). Commonality of the
gene programs induced by effectors of apoptosis in androgen-dependent
and -independent prostate cells. Cell Growth Differ. 5, 457–466.
Sells, S.F., Han, S.S., Muthukkumar, S., Maddiwar, N., Johnstone, R.,
Boghaert, E., Gillis, D., Liu, G., Nair, P., Monnig, S., et al. (1997). Expression
and function of the leucine zipper protein Par-4 in apoptosis. Mol. Cell. Biol.
17, 3823–3832.
Symmans, W.F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V.,
Assad, L., Poniecka, A., Hennessy, B., Green, M., et al. (2007).
Measurement of residual breast cancer burden to predict survival after neoad-
juvant chemotherapy. J. Clin. Oncol. 25, 4414–4422.
Vetterkind, S., and Morgan, K.G. (2009). The pro-apoptotic protein Par-4 facil-
itates vascular contractility by cytoskeletal targeting of ZIPK. J. Cell. Mol. Med.
13, 887–895.
Vetterkind, S., Illenberger, S., Kubicek, J., Boosen, M., Appel, S., Naim, H.Y.,
Scheidtmann, K.H., and Preuss, U. (2005). Binding of Par-4 to the actin cyto-
skeleton is essential for Par-4/Dlk-mediated apoptosis. Exp. Cell Res. 305,
392–408.
Yamashiro, S., Yamakita, Y., Totsukawa, G., Goto, H., Kaibuchi, K., Ito, M.,
Hartshorne, D.J., and Matsumura, F. (2008). Myosin phosphatase-targeting
subunit 1 regulates mitosis by antagonizing polo-like kinase 1. Dev. Cell 14,
787–797.
